Mid-cap Healthcare company Zai Lab has moved -3.2% so far today on a volume of 100,034, compared to its average of 665,185. In contrast, the S&P 500 index moved -0.4%
Zai Lab trades -60.86% away from its average analyst target price of $93.39 per share. The 11 analysts following the stock have set target prices ranging from $70 to $199, and on average have given Zai Lab a rating of strong_buy.
Below are some factors that could be affecting the stocks's performance and analyst recommendation:
Based on its trailing earning per share of -3.46, Zai Lab has a trailing 12 month Price to Earnings (P/E) ratio of -10.6 while the S&P 500 average is 15.97
ZLAB has a forward P/E ratio of -14.5 based on its forward 12 month price to earnings (Eps) is $-2.52 per share
The company has a price to earnings growth (PEG) ratio of -0.17 -- a number near or below 1 signifying that Zai Lab is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.7 compared to its sector average of 4.07
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Based in Shanghai, the company has 1,951 full time employees and a market cap of $3,736,214,016.
If you would like more in-depth discussions of stocks such as Zai Lab, subscribe to our free newsletter!